While there could be concern about increasing the levels of Hsp90 within the tumor, we observed displacement of the Hsp90 client proteins suggesting that HS201 or its metabolites may still retain Hsp90-inhibitory effects. This evidence concerns the gene HSP90AA1 and neoplasm.